BioNTech Escalates Legal Battle with Moderna Over mRNA Patents

BioNTech files a major patent lawsuit against Moderna as it pivots from declining COVID-19 vaccine revenue to focus on its oncology pipeline and future growth.

As it prepares to release its annual financial results, BioNTech SE has initiated a significant patent infringement lawsuit against its rival Moderna. The legal action, filed in a Delaware federal court, marks a new phase in the competitive and legal tensions between the two pioneers of mRNA technology. BioNTech alleges that Moderna's updated COVID-19 vaccine, mNEXSPIKE, utilizes proprietary technology without authorization, specifically intellectual property related to dosing efficiency.

Strategic Move Amid Shifting Revenues

This legal offensive comes at a pivotal moment for the Mainz-based company. With revenue from its COVID-19 vaccine, Comirnaty, expected to decline, BioNTech is aggressively seeking to monetize its research portfolio. The timing, just days before its March 10, 2026, earnings report, is viewed by market observers as a strategic maneuver to strengthen its market position. The lawsuit seeks compensation for what BioNTech claims is the unauthorized use of its intellectual property.

For Moderna, the stakes are considerable. Financial documents indicate that the mNEXSPIKE vaccine is projected to account for over half of Moderna's COVID-19 shot sales for the current season. A successful claim by BioNTech could therefore have substantial financial implications.

Financial Fortitude and Future Headwinds

BioNTech enters this period from a position of notable financial strength. As of the end of 2025, the company reported holding cash, cash equivalents, and security investments totaling €17.2 billion. This substantial reserve is seen as a crucial buffer for the coming transition.

However, the operating environment is becoming more challenging. Management anticipates a decrease in Comirnaty revenues for 2026, citing factors including revised vaccination guidelines in the United States and the industry-wide shift from government bulk purchasing to the private commercial market. Despite a share price increase of approximately 12% since the start of the year, recent volatility reflects investor uncertainty regarding the company's near-term revenue streams.

Pivoting Toward Oncology Leadership

The core long-term strategy involves a deliberate transformation into a fully-fledged oncology company, reducing dependence on the pandemic-related business. To this end, BioNTech is channeling resources into its cancer drug pipeline, with plans to initiate 15 Phase 3 clinical trials by the end of 2026.

This strategic expansion is being supported by recent corporate developments. The acquisition of CureVac has been finalized, and the appointment of Kylie Jimenez as the new Chief People Officer is designed to steer the global talent strategy required for this ambitious growth. Company leadership has been clear that 2026 will be an investment year, with no revenue expected from oncology products. The focus remains squarely on clinical development and generating trial data that will ultimately determine the long-term valuation of the company.